$BMRN News

BioMarin (NASDAQ:BMRN) Stands Out as an Undervalued Stock with Solid Fundamentals

BioMarin Pharmaceutical (BMRN) Agrees $490 Million Deal For Oral Rare Bone Disease Program

Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today

BioMarin Pharmaceutical (BMRN)’s Alesta Deal Adds New Growth Potential in Rare Diseases

BioMarin acquiring Alesta Therapeutics for $275 million

BioMarin spends up to $490m for Alesta’s bone disease candidate

BMO Capital Initiates Coverage On BioMarin Pharmaceutical with Outperform Rating, Announces Price Target of $98

BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why

BioMarin Pharmaceutical's Alesta Deal Strengthens Long-Term Growth Outlook, Wedbush Says

BioMarin Shares Jump After $275 Million Deal to Acquire Alesta Therapeutics

BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline

BioMarin acquires experimental drug for rare bone disorder in $275M deal

HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $59

BioMarin Pharmaceutical Signs Agreement To Acquire Alesta Therapeutics For $275M

Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $88

Does BioMarin’s Raised 2026 Outlook and ESOP Shelf Offering Reshape the Bull Case for BMRN?

Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $111

BioMarin Pharmaceutical (BMRN) Updates Guidance And Files Shelf Registration, Is It Still Below Fair Value?

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know